This projet consits of preclinical study and establishment of production process of clinically graded umbilical cord-deived stem cells (CordStem-ST) for the development of stel cell therapy for ischemic stroke.
1. Establishment of stem cell bank and ...
This projet consits of preclinical study and establishment of production process of clinically graded umbilical cord-deived stem cells (CordStem-ST) for the development of stel cell therapy for ischemic stroke.
1. Establishment of stem cell bank and product process system for development of CordStem-ST as end product for clinical trial: Establishment of product process of GMP-graded stem cells.
2. Establishment of behavioral, histological, and biochemical method for standarization of efficacy analysis of CordStem-ST in animal stroke model
3. Comparision study for determination of optimal treatment condition of CordStem-ST: Repetitive IV injection of two hundred million cells as best treatment choice for ischemic stroke
4. Safety analysis of CordStem-ST: Confirmation of safety of CordStem-ST in single/double dose toxicity test, cell remaining tracking test, and tumorogenecity test
5. Clarification of mode of action (MoA) of CordStem-ST: Anti-inflammatiory effect and promoting effect of endogenous tissue repair are major therapeutic mechanism of CordStem-ST in stroke.
6. Preparation of GCP for clinical trial of CordStem-ST in human stroke: IND filing for phase I/IIa SIT clinical trial
Through preclinical study, we accomplished our project mission of KFDA approval for clinical trial of CordStem-ST in human stroke.